Focal hand dystonia

Summary

Focal hand dystonia (MONDO:0000482) is a disease and 11 clinical trials. A subtype of focal dystonia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	focal hand dystonia
Mondo ID	MONDO:0000482
DOID	DOID:0050841
SNOMED CT	52008007
UMLS	C0154676
MedGen	57821
GARD	0027530
Is cancer (heuristic)	no

Also known as: hand and arm dystonia · writer’s cramp

Disease family

This is a subtype of focal dystonia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › movement disorder › extrapyramidal and movement disease › dystonic disorder › focal dystonia › focal hand dystonia

Related subtypes (11): anismus, cervical dystonia, oculogyric crisis, spasmodic dystonia, craniofacial dystonia, X-linked dystonia-parkinsonism, torsion dystonia 7, benign essential blepharospasm, dystonia 23, oromandibular dystonia, dystonia, focal, task-specific

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE2	2
PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03977493	PHASE3	RECRUITING	IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia
NCT04611009	PHASE2	RECRUITING	Video-supervised Motor and Awareness Training in Writer’s Cramp
NCT00106782	PHASE2	COMPLETED	Transcranial Electrical Polarization to Treat Focal Hand Dystonia
NCT02504905	EARLY_PHASE1	COMPLETED	Propensity to Develop Plasticity in the Parieto-Motor Networks in Dystonia From the Perspective of Abnormal High-Order Motor Processing
NCT03042962	Not specified	RECRUITING	Brain Networks in Dystonia
NCT00325091	Not specified	COMPLETED	Long-Term Motor Learning in Focal Hand Dystonia
NCT00376753	Not specified	COMPLETED	Muscle Contraction in Patients With Focal Hand Dystonia
NCT00579033	Not specified	UNKNOWN	Somatosensory Processing in Focal Hand Dystonia
NCT03085745	Not specified	UNKNOWN	Sensorimotor Mapping in Patients With Writer’s Cramp
NCT03664375	Not specified	COMPLETED	Impact Of Physiotherapy And Botox In Improving Functional Outcomes Among Post Stroke Focal Dystonia Patients
NCT03797638	Not specified	COMPLETED	Characterization of Manual Dexterity by Finger Force Manipuladum (FFM) in Patients With Writer’s Cramp and in Control Subjects

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CHEMBL46909	0	1